Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1323-1327

  Keskikuru, Riitta ^a   Bloigu, Risto ^b   Risteli, Juha ^b   Kataja, Vesa ^a   Jukkola, Arja ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; ICTP; Prognostic factor

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; ESTROGEN RECEPTOR; PEPTIDE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG CARCINOMA; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036836283     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1323     Document Type: Article

References (21)

1. Foekens JA, Schmitt M, van Putten WLJ, Peters WI, Bontenbal B, Janicke F and Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
2. Clark CM, Mathieu M-C, Owens MA, Dressier LG, Eudney L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG and Abeloff MD: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10: 428-432, 1992.
3. Malmström P, Bendahl P-O, Boiesen P, Brunner N, Idvall I and Fernö K: S-phase fraction and urokinase activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19: 2010-2019, 2001.
4. Talvensaari-Mattila A, Pääkkö P, Blanco-Sequeiras G and Turpeniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998. (Pubitemid 28419068)
5. Safi F, Kohler I, Rottinger E and Beger H-G: The value of the tumor marker CA-15-3 in diagnosing and monitoring breast cancer. Cancer 69: 574-584, 1991.
6. Van der Rest M and Garrone R: Collagen family of proteins. FASEB J 5: 2814-2823, 1991.
7. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S and Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 73: 1073-1079, 1996.
8. Kylmälä T, Tammela T, Risteli L, Risteli J, Kontturi M and Elomaa I: Type I degradation product (ICTP) gives information about the nature of bone metastases and has prognostic values in prostate cancer. Br J Cancer 71: 1061-1064, 1995.
9. Aruga A, Koizumi M, Hotta R, Takahashi S and Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastases from lung cancer. Br J Cancer 76: 760-764, 1997. (Pubitemid 27379743)
10. Ylisirniö S, Sassi M-L, Risteli J, Turpeniemi-Hujanen T and Jukkola A: Serum type I collagen degradation markers ICTP and Cross-laps are factors for poor survival in lung cancer. Anticancer Res 19: 5577-5588, 1999.
11. Santala M, Risteli L, Puistola U, Risteli J and Kauppila A: Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma. Ann Med 27: 57-61, 1995.
12. Santala M, Simojoki M, Risteli J, Risteli L and Kauppila A: Type I and type III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4091-4096, 1999. (Pubitemid 30013790)
13. Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääkkö P, Risteli J, Kinnula VL, Turpeniemi-Hujanen T and Jukkola A: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) are associated with poor prognosis in lung cancer. Clin Cancer Res 7: 1633-1637, 2001. (Pubitemid 32708629)
14. Jukkola A, Tähtelä R, Thölix E, Vuorinen K, Blanco G, Risteli L and Risteli J: Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57: 5517-5520, 1997. (Pubitemid 28006758)
15. Keskikuru R, Kataja V, Eskelinen M, Uusitupa M, Johansson R, Risteli L, Risteli J and Jukkola A: Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Anticancer Res 19: 4481-4484, 1999. (Pubitemid 30042810)
16. Champers AF and Matrison LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 17: 1260-1270, 1997.
17. Sassi M-L, Eriksen H, Risteli L, Niemi S, Mansell J, Gouren M and Risteli J: Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenity by treatment with cathepsin K. Bone 26: 367-373, 2000. (Pubitemid 30136127)
18. Delmas P: Standardization of bone marker nomenclature. Clin Chem 47: 1497, 2001.
19. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1993.
20. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993. (Pubitemid 23147516)
21. Kähäri V-M and Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann Med 31: 34-35, 1999.